Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | UGCG | Q16739 | 4/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 4/20 | 0.43 |
| ▸ | GBA1 | P04062 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21068524 | 0.95 | KDM4E (0.50) | KDM4EPOLBL3MBTL1TDP1UGCG | |
| SCHEMBL9276198 | 0.87 | KDM4E (0.62) | KDM4EPOLBUGCGGBA2GBA1 | |
| SCHEMBL19437686 | 0.84 | KDM4E (0.51) | KDM4EPOLBL3MBTL1TDP1UGCG | |
| SCHEMBL19437584 | 0.82 | KDM4E (0.53) | KDM4EPOLBL3MBTL1TDP1UGCG | |
| SCHEMBL8743553 | 0.80 | KDM4E (0.50) | KDM4EPOLBUGCGGBA2GBA1 | |
| SCHEMBL20937625 | 0.80 | KDM4E (0.47) | KDM4EPOLBL3MBTL1TDP1UGCG | |
| SCHEMBL8743637 | 0.80 | TSHR (0.52) | KDM4EPOLBTSHR | |
| SCHEMBL21068541 | 0.80 | L3MBTL1 (0.42) | KDM4EPOLBL3MBTL1TDP1UGCG | |
| SCHEMBL19437656 | 0.79 | L3MBTL1 (0.47) | KDM4EPOLBL3MBTL1TDP1UGCG | |
| SCHEMBL9011624 | 0.79 | TSHR (0.67) | L3MBTL1TDP1UGCGGBA2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491623-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | KDM4E 647/4885POLB 3468/4885L3MBTL1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.